Objective: This study aimed to describe the clinical and paraclinical characteristics and to evaluate the outcomes of adjuvant chemotherapy with the XELOX regimen in patients with high-risk stage II and stage III colon cancer at Thai Binh General Hospital. Subjects and Methods: A retrospective descriptive study was conducted on 70 patients with high-risk stage II and stage III colon cancer who underwent curative surgery followed by adjuvant chemotherapy with the XELOX regimen at Thai Binh General Hospital from January 2022 to December 2025. Clinical and paraclinical features, treatment course, disease-free survival, overall survival, and treatment-related toxicities were collected and analyzed. Results: The disease was most common in patients over 50 years of age, with those over 60 accounting for 41.4%; males represented 60.0%. The most frequent symptoms were abdominal pain (74.3%), digestive disturbances (67.1%), and bloody mucous stools (58.6%). Tumors were mainly located in the left colon (31.4%) and right colon (37.1%); adenocarcinoma accounted for 85.7%. Stage III disease predominated (74.3%), with stage IIIb accounting for 40.0%. A total of 77.1% of patients completed all 8 cycles of chemotherapy, and 74.3% received 90–100% of the standard dose. Disease-free survival rates at 12, 24, and 36 months were 92.9%, 82.9%, and 74.2%, respectively; corresponding overall survival rates were 98.6%, 92.9%, and 84.3%. Three-year disease-free survival was significantly associated with postoperative CEA levels. Three-year overall survival was significantly associated with disease stage, nodal status, and postoperative CEA levels. Toxicities were mostly grade 1–2, with few grade 3 events and no grade 4 toxicities observed. Conclusion: Adjuvant XELOX chemotherapy for high-risk stage II and stage III colon cancer at Thai Binh General Hospital showed favorable survival outcomes, good treatment completion rates, and acceptable toxicity, indicating good tolerability in clinical practice.
ADJUVANT XELOX CHEMOTHERAPY OUTCOMES IN HIGH-RISK STAGE II AND STAGE III COLON CANCER: EVIDENCE FROM THAI BINH GENERAL HOSPITAL
27
Views
0
Downloads
Abstract
Keywords
colon cancer, adjuvant chemotherapy, XELOX, disease-free survival, overall survival.
References
[1]
1. International Agency for Research on Cancer. Cancer today: Data visualization tools for exploring the global cancer burden in 2022. Global Cancer Observatory, 2024
Google Scholar
[2]
2. Baxter NN, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, et al. Adjuvant therapy for stage II colon cancer: ASCO guideline update. J Clin Oncol. 2022;40(8):892-910. doi:10.1200/JCO.21.02538.
Google Scholar
[3]
3. Argilés G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(10):1291-1305. doi:10.1016/j.annonc.2020.06.022.
Google Scholar
[4]
4. Schmoll HJ, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, et al. Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial. J Clin Oncol. 2015;33(32):3733-3740. doi:10.1200/JCO.2015.60.9107.
Google Scholar
[5]
5. WHO Classification of Tumours Editorial Board. Digestive System Tumours. 5th ed. Vol 1. Lyon, France: International Agency for Research on Cancer; 2019.
Google Scholar
[6]
6. André T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol. 2015;33(35):4176-4187. doi:10.1200/JCO.2015.63.4238.
Google Scholar
[7]
7. Xie HL, Chen L, Cao HY, Chen HY, Chen D, Cao YB. The prognostic value of the postoperative serum CEA levels/preoperative serum CEA levels ratio in colorectal cancer patients with high preoperative serum CEA levels. Cancer Manag Res. 2019;11:7499-7511. doi:10.2147/CMAR.S213580.
Google Scholar